NCT02450903 - LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 21, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

May 24, 2018

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG

LDK378

Oral LDK378 750mg once daily

Trial Locations (9)

Novartis Investigative Site, Nagoya

Novartis Investigative Site, Kashiwa

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Sakyo Ku

Novartis Investigative Site, Natori-shi

Novartis Investigative Site, Okayama

Novartis Investigative Site, Ōsaka-sayama

Novartis Investigative Site, Chuo Ku

Novartis Investigative Site, Koto Ku